000272964 001__ 272964
000272964 005__ 20241208000026.0
000272964 0247_ $$2doi$$a10.1002/alz.14230
000272964 0247_ $$2pmid$$apmid:39291737
000272964 0247_ $$2pmc$$apmc:PMC11567826
000272964 0247_ $$2ISSN$$a1552-5260
000272964 0247_ $$2ISSN$$a1552-5279
000272964 0247_ $$2altmetric$$aaltmetric:167941691
000272964 037__ $$aDZNE-2024-01343
000272964 041__ $$aEnglish
000272964 082__ $$a610
000272964 1001_ $$aLiu, Shiwei$$b0
000272964 245__ $$aPlasma miRNAs across the Alzheimer's disease continuum: Relationship to central biomarkers.
000272964 260__ $$aHoboken, NJ$$bWiley$$c2024
000272964 3367_ $$2DRIVER$$aarticle
000272964 3367_ $$2DataCite$$aOutput Types/Journal article
000272964 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1732007756_11165
000272964 3367_ $$2BibTeX$$aARTICLE
000272964 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000272964 3367_ $$00$$2EndNote$$aJournal Article
000272964 520__ $$aMicroRNAs (miRNAs) play important roles in gene expression regulation and Alzheimer's disease (AD) pathogenesis.We investigated the association between baseline plasma miRNAs and central AD biomarkers from the Alzheimer's Disease Neuroimaging Initiative (ADNI; N = 803): amyloid, tau, and neurodegeneration (A/T/N). Differentially expressed miRNAs and their targets were identified, followed by pathway enrichment analysis. Machine learning approaches were applied to investigate the role of miRNAs as blood biomarkers.We identified nine, two, and eight miRNAs significantly associated with A/T/N positivity, respectively. We identified 271 genes targeted by amyloid-related miRNAs with estrogen signaling receptor-mediated signaling among the enriched pathways. Additionally, 220 genes targeted by neurodegeneration-related miRNAs showed enrichment in pathways including the insulin growth factor 1 pathway. The classification performance of demographic information for A/T/N positivity was increased up to 9% with the inclusion of miRNAs.Plasma miRNAs were associated with central A/T/N biomarkers, highlighting their potential as blood biomarkers.We performed association analysis of microRNAs (miRNAs) with amyloid/tau/neurodegeneration (A/T/N) biomarker positivity. We identified dysregulated miRNAs for A/T/N biomarker positivity. We identified Alzheimer's disease biomarker-specific/common pathways related to miRNAs. miRNAs improved the classification for A/T/N positivity by up to 9%. Our study highlights the potential of miRNAs as blood biomarkers.
000272964 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000272964 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000272964 650_7 $$2Other$$aAlzheimer's disease
000272964 650_7 $$2Other$$aamyloid
000272964 650_7 $$2Other$$abiomarkers
000272964 650_7 $$2Other$$aclassification
000272964 650_7 $$2Other$$amicroRNAs
000272964 650_7 $$2Other$$aneurodegeneration
000272964 650_7 $$2Other$$aplasma
000272964 650_7 $$2Other$$atau
000272964 650_7 $$2NLM Chemicals$$aBiomarkers
000272964 650_7 $$2NLM Chemicals$$aMicroRNAs
000272964 650_7 $$2NLM Chemicals$$atau Proteins
000272964 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000272964 650_2 $$2MeSH$$aHumans
000272964 650_2 $$2MeSH$$aAlzheimer Disease: blood
000272964 650_2 $$2MeSH$$aAlzheimer Disease: genetics
000272964 650_2 $$2MeSH$$aBiomarkers: blood
000272964 650_2 $$2MeSH$$aMicroRNAs: blood
000272964 650_2 $$2MeSH$$aMicroRNAs: genetics
000272964 650_2 $$2MeSH$$aFemale
000272964 650_2 $$2MeSH$$aMale
000272964 650_2 $$2MeSH$$aAged
000272964 650_2 $$2MeSH$$aAged, 80 and over
000272964 650_2 $$2MeSH$$aMachine Learning
000272964 650_2 $$2MeSH$$atau Proteins: blood
000272964 650_2 $$2MeSH$$aAmyloid beta-Peptides: blood
000272964 7001_ $$aPark, Tamina$$b1
000272964 7001_ $$0P:(DE-2719)2812548$$aKrüger, Dennis M$$b2$$udzne
000272964 7001_ $$0P:(DE-2719)2811063$$aPena Centeno, Tonatiuh$$b3$$udzne
000272964 7001_ $$0P:(DE-2719)2810773$$aBurkhardt, Susanne$$b4$$udzne
000272964 7001_ $$0P:(DE-2719)2810585$$aSchutz, Anna-Lena$$b5$$udzne
000272964 7001_ $$aHuang, Yen-Ning$$b6
000272964 7001_ $$aRosewood, Thea$$b7
000272964 7001_ $$aChaudhuri, Soumilee$$b8
000272964 7001_ $$aCho, MinYoung$$b9
000272964 7001_ $$aRisacher, Shannon L$$b10
000272964 7001_ $$aWan, Yang$$b11
000272964 7001_ $$aShaw, Leslie M$$b12
000272964 7001_ $$0P:(DE-2719)2811099$$aSananbenesi, Farahnaz$$b13$$udzne
000272964 7001_ $$aBrodsky, Alexander S$$b14
000272964 7001_ $$aLin, Honghuang$$b15
000272964 7001_ $$aKrunic, Andre$$b16
000272964 7001_ $$aBlusztajn, Jan Krzysztof$$b17
000272964 7001_ $$aSaykin, Andrew J$$b18
000272964 7001_ $$00000-0002-1873-3064$$aDelalle, Ivana$$b19
000272964 7001_ $$0P:(DE-2719)2000047$$aFischer, Andre$$b20$$udzne
000272964 7001_ $$aNho, Kwangsik$$b21
000272964 7001_ $$aInitiative, Alzheimer's Disease Neuroimaging$$b22$$eCollaboration Author
000272964 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz.14230$$gVol. 20, no. 11, p. 7698 - 7714$$n11$$p7698 - 7714$$tAlzheimer's and dementia$$v20$$x1552-5260$$y2024
000272964 8564_ $$uhttps://pub.dzne.de/record/272964/files/DZNE-2024-01343.pdf$$yOpenAccess
000272964 8564_ $$uhttps://pub.dzne.de/record/272964/files/DZNE-2024-01343.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000272964 909CO $$ooai:pub.dzne.de:272964$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000272964 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812548$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000272964 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811063$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000272964 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810773$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000272964 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810585$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000272964 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811099$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000272964 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000047$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b20$$kDZNE
000272964 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000272964 9141_ $$y2024
000272964 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000272964 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-25
000272964 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000272964 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2023-10-25
000272964 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-25$$wger
000272964 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-25
000272964 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2023-10-25
000272964 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000272964 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000272964 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000272964 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-25
000272964 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000272964 9201_ $$0I:(DE-2719)1410002$$kAG Fischer$$lEpigenetics and Systems Medicine in Neurodegenerative Diseases$$x0
000272964 9201_ $$0I:(DE-2719)1440016$$kBioinformatics Unit (Göttingen)$$lBioinformatics and Genome Dynamics Core (Göttingen)$$x1
000272964 9201_ $$0I:(DE-2719)1410004$$kAG Sananbenesi$$lGenome Dynamics in Neurodegenerative Diseases$$x2
000272964 980__ $$ajournal
000272964 980__ $$aVDB
000272964 980__ $$aUNRESTRICTED
000272964 980__ $$aI:(DE-2719)1410002
000272964 980__ $$aI:(DE-2719)1440016
000272964 980__ $$aI:(DE-2719)1410004
000272964 9801_ $$aFullTexts